Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710253 · ClinicalTrials.gov registry record · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
A Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 5
- Study locations
NCT02710253: Recruiting Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT02710253 is a Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 230 participants, below the 951-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02710253, a Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to control the cancer after the disease has gotten worse after receiving immunotherapy in patients with cancer that has spread to the other places in the body.
Primary Outcome
To be evaluable for efficacy patients must receive at least one set of systemic imaging \>= 4 weeks after completion of radiation. For all control cohorts, efficacy will be evaluated based off of retrospective review of control patients. Corollary investigation will be conducted utilizing immune-related response criteria (ir-RC). Significance testing will assess differences in the frequency of disease control rate via Fisher Exact (if n =\< 20) or Chi-squared (if n \> 20) test.
Conditions Studied
Interventions
- RADIATION External Beam Radiation Therapy
- RADIATION Stereotactic Body Radiation Therapy
- OTHER Laboratory Biomarker Analysis
Study Locations (5)
Texas
- MD Anderson in The Woodlands - Conroe
- M D Anderson Cancer Center - Houston
- MD Anderson West Houston - Houston
- MD Anderson League City - League City
- MD Anderson in Sugar Land - Sugar Land
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
What NCT02710253 shows while recruiting
NCT02710253 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which External Beam Radiation Therapy is the first listed.
NCT02710253 lists 5 locations in 1 state (Texas).
Frequently Asked Questions
What is clinical trial NCT02710253 about?
NCT02710253 is a clinical study titled "Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy". This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to...
What is the current status of trial NCT02710253?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2016-05-25. Estimated completion is 2026-05-30.
What conditions does trial NCT02710253 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm.
What interventions are being tested in trial NCT02710253?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Stereotactic Body Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02710253?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710253 being conducted?
This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02710253's enrollment target sits among peer trials
230 28th of 104 higher than 77 of 104 other Hematopoietic and Lymphoid Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic and Lymphoid Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
ACTIVE NOT RECRUITING · Phase 2
-
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
ACTIVE NOT RECRUITING · Phase 2
-
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
- NCT03871075 · 230 participants · NA
Intermittent Pneumatic Compression With and Without Exercise to Improve Functioning in Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI